Eugia Pharma (malta) Limited Pharmaceutical Import Profile — Malta (DGFT 2022–2026)

Name: Eugia Pharma (malta) Limited Pharmaceutical Import Records from India — 7 Products, $10.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eugia Pharma (malta) Limited — Pharmaceutical Importer Profile (2026) | 7 Products, $10.2M Trade | TransData Nexus

Eugia Pharma (malta) Limited

Pharmaceutical Importer · Malta · Advanced Antibiotics Focus · $10.2M Total Trade · DGFT Verified

Eugia Pharma (malta) Limited is a pharmaceutical importer based in Malta with a total trade value of $10.2M across 7 products in 3 therapeutic categories. Based on 326 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eugia Pharma (malta) Limited sources from 2 verified Indian suppliers, with Eugia Pharma Specialities Limited accounting for 98.0% of imports.

Eugia Pharma (malta) Limited — Import Portfolio & Supplier Network

Eugia Pharma (malta) Limited import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eugia Pharma (malta) Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Eugia Pharma Specialities Limited	$2.1M	89	98.0%
Aurobindo Pharma Limited	$42.6K	5	2.0%

Eugia Pharma (malta) Limited sources from 2 verified Indian suppliers across .

What Formulations Does Eugia Pharma (malta) Limited Import?

Formulation	Value	Ships
Ertapenem for injection 1	$250.0K	5
Ertapenem for injection	$100.0K	2
Gemcitabine concentrated solution for infusion 40MG/ML 2000 MG/50 ML gemcitabine concentrated solution for infusion	$95.1K	2
Paclitaxel injection 300MG/50ml6mg/mlpaclitaxel 6MG/ML concentrate for solution for	$77.5K	2
Paclitaxel injection 300MG/50ml6mg/mlpaclitaxel 6MG/ML concentrate for solution for	$67.1K	2
Meropenem for inj1g/vialmeropenem aurovitas 1000 MG 1 vial b.no.2mi23050a manufacturing .d.04/2023	$50.0K	1
Ertapenem for injection 1 g/vial	$50.0K	1
Levetiracetam oral solution 100MG/ML levetiracetam aurovitas 100MG/ML levetiracetam concentrate for solution for	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1g polvo para conc.batch-2ei23173a manufacturing dt-09/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1g polvo para conc.batch-2ei23174a manufacturing dt-09/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1g polvo para conce.batch-2ei23181a manufacturing dt-10/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem arrow 1g poudre pour solution.batch-2ei23172a manufacturing dt-09/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1g polvo para conce.batch-2ei23177a manufacturing dt-10/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1 g polvo para con.batch-2ei23185a manufacturing dt-10/2023exp	$50.0K	1
Ertapenem for injection 1 g/vialertapenem aurovitas 1 g polvo para con.batch-2ei23182a manufacturing dt-10/2023exp	$50.0K	1

Eugia Pharma (malta) Limited imports 80 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ertapenem	Advanced Antibiotics	$4.0M	79	1.9%	4
2	Gemcitabine	Oncology	$3.4M	118	7.2%	2
3	Piperacillin	Advanced Antibiotics	$800.0K	16	0.9%	6
4	Doxorubicin	Oncology	$763.1K	56	1.1%	19
5	Vinorelbine	Advanced Oncology	$504.9K	17	12.3%	2
6	Docetaxel	Oncology	$416.1K	33	1.1%	19
7	Fulvestrant	Advanced Oncology	$350.0K	7	2.4%	9

Eugia Pharma (malta) Limited imports 7 pharmaceutical products across 3 categories into Malta totaling $10.2M.

Eugia Pharma (malta) Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eugia Pharma (Malta) Limited, established on October 14, 2021, is a pharmaceutical importer based in Malta. The company is located at Vault 14, Level 2, Valletta Waterfront, Floriana FRN 1914. Eugia Pharma (Malta) Limited is a subsidiary of Eugia Pharma Specialities Limited, an Indian pharmaceutical company known for its focus on specialty generics, including oncology and injectables. In Malta, Eugia Pharma (Malta) Limited plays a significant role in the pharmaceutical distribution network, importing a diverse range of finished pharmaceutical formulations to meet the healthcare needs of the Maltese population.

2Distribution Network

Eugia Pharma (Malta) Limited operates a centralized distribution model from its facility in Floriana, Malta. The company imports finished pharmaceutical formulations from India, primarily sourced from Eugia Pharma Specialities Limited and Aurobindo Pharma Limited. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Malta enables efficient distribution across the island and potentially to neighboring regions.

3Industry Role

In Malta's pharmaceutical supply chain, Eugia Pharma (Malta) Limited functions as a primary wholesaler and importer. The company focuses on sourcing and distributing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, to meet the demands of local healthcare providers and pharmacies. By importing a diverse range of products, Eugia Pharma (Malta) Limited ensures a steady supply of essential medications to the Maltese market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eugia Pharma (malta) Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eugia Pharma (Malta) Limited's sourcing strategy is heavily concentrated on a limited number of suppliers. The majority of its imports are from Eugia Pharma Specialities Limited, accounting for approximately 98% of the total import value. This high dependency on a single supplier could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the company's diversified product portfolio, with 80 unique formulations across various therapeutic categories, may mitigate some of these risks by reducing reliance on any single product line.

2Supply Chain Resilience

Eugia Pharma (Malta) Limited's supply chain resilience is closely tied to the stability and reliability of its primary supplier, Eugia Pharma Specialities Limited. The company's focus on importing finished pharmaceutical formulations from India suggests a streamlined supply chain with established shipping routes. While the company imports from multiple suppliers, the dominance of Eugia Pharma Specialities Limited in its sourcing strategy indicates a reliance on this supplier for a significant portion of its product range. Ensuring the regulatory compliance and operational stability of this supplier is crucial for maintaining a resilient supply chain.

Strategic Implications

Importing Pharmaceuticals into Malta — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malta

1Regulatory Authority & Framework

In Malta, the Medicines Authority is the regulatory body responsible for overseeing the importation, distribution, and marketing of medicinal products. The regulatory framework governing pharmaceutical imports includes adherence to Good Manufacturing Practice (GMP) guidelines, which ensure that medicinal products are consistently produced and controlled to quality standards appropriate to their intended use. (medicinesauthority.gov.mt) For Indian generics, the marketing authorization pathway involves obtaining approval from the Medicines Authority, which assesses the quality, safety, and efficacy of the products before granting authorization for sale in Malta.

2Import Licensing & GMP

Import licensing in Malta requires compliance with GMP standards, ensuring that imported medicinal products meet the necessary quality and safety criteria. Certificates such as EU GMP, WHO GMP, or PIC/S are recognized by the Medicines Authority and are essential for the importation process. Additionally, wholesale distribution authorization is required for entities involved in the distribution of medicinal products within Malta. This authorization ensures that distributors adhere to the regulatory standards set forth by the Medicines Authority.

Quality & Labeling

Eugia Pharma (malta) Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eugia Pharma (Malta) Limited's product strategy focuses on importing finished pharmaceutical formulations across three therapeutic categories: Advanced Antibiotics (46.8%), Oncology (44.8%), and Advanced Oncology (8.4%). This strategic focus aligns with the growing demand for specialized treatments in Malta, particularly in the areas of infectious diseases and cancer care. The company's portfolio concentration, with the top five products accounting for 92.5% of total imports, indicates a targeted approach to meet specific healthcare needs.

2Sourcing Profile

Eugia Pharma (Malta) Limited's sourcing strategy is centered on importing generic pharmaceutical products, primarily from India. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, reflects a focus on ready-to-market products that can be swiftly distributed within Malta. India's established reputation for producing high-quality generics makes it a strategic partner for Eugia Pharma (Malta) Limited's procurement needs.

3Market Positioning

Based on its product mix, Eugia Pharma (Malta) Limited serves multiple segments of the Maltese pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on advanced antibiotics and oncology products positions it to meet the needs of healthcare providers requiring specialized treatments. By importing a diverse range of formulations, Eugia Pharma (Malta) Limited ensures a comprehensive supply of essential medications across various healthcare settings.

Seller's Guide — How to Become a Supplier to Eugia Pharma (malta) Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Maltese market by establishing relationships with Eugia Pharma (Malta) Limited. Diversifying the product range and offering competitive pricing could attract the company's interest. However, the existing strong partnership between Eugia Pharma (Malta) Limited and Eugia Pharma Specialities Limited may present challenges for new entrants. Understanding the regulatory requirements and aligning with the company's sourcing strategy will be crucial for success.

2Requirements & Qualifications

Indian exporters seeking to supply Eugia Pharma (Malta) Limited and the Maltese market must ensure that their products comply with EU GMP standards. Obtaining certifications such as EU GMP, WHO GMP, or PIC/S is essential for import authorization. Additionally, products must meet labeling requirements in the Maltese language and adhere to serialization mandates. Establishing a robust quality management system and maintaining compliance with regulatory standards will enhance the prospects of successful market entry.

3How to Approach

Frequently Asked Questions — Eugia Pharma (malta) Limited

What products does Eugia Pharma (malta) Limited import from India?

Eugia Pharma (malta) Limited imports 7 pharmaceutical products across 3 categories. Top imports: Ertapenem ($4.0M), Gemcitabine ($3.4M), Piperacillin ($800.0K), Doxorubicin ($763.1K), Vinorelbine ($504.9K).

Who supplies pharmaceuticals to Eugia Pharma (malta) Limited from India?

Eugia Pharma (malta) Limited sources from 2 verified Indian suppliers. The primary supplier is Eugia Pharma Specialities Limited (98.0% of imports, $2.1M).

What is Eugia Pharma (malta) Limited's total pharmaceutical import value?

Eugia Pharma (malta) Limited's total pharmaceutical import value from India is $10.2M, based on 326 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eugia Pharma (malta) Limited focus on?

Eugia Pharma (malta) Limited imports across 3 categories. The largest: Advanced Antibiotics (46.8%), Oncology (44.8%), Advanced Oncology (8.4%).

Get Full Eugia Pharma (malta) Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.